IMPLANTABLE PHOTOMEDICINE FOR LIFE
Incando Therapeutics is a medical device company developing light-based therapies for intractable, hard to treat cancers.
Incando Therapeutics is developing a unique medical device-based phototherapy system for the treatment of Glioblastoma multiforme (GBM), a devastating and fatal cancer of the brain. Patented wireless powering technology enables our Deeplight Photodynamic therapy to be used repeatably and with a better safety profile than current chemoradiotherapy treatments.
Our diverse team brings together decades of engineering and scientific expertise and our internationally renowned scientific and clinical partners work at the frontiers of cancer therapy.
AN URGENT NEED FOR NEW GBM TREATMENTS
The current standard of care for glioblastoma (GBM) patients is a surgical resection of the tumor, followed by a 6-week intensive regimen of chemotherapy and radio therapy. Afterwards, patients are monitored every few months for signs of tumor recurrence. Unfortunately, the tumor does recur for almost all patients.
Today, patients and doctors have few options once the tumor returns (recurrence). Radiation therapy is not possible more than once for the brain, and many GBMs become resistant to chemotherapy.
- 13% of all brain tumors, but 60% of all brain tumor deaths
- Over 13,000 patients per year (USA), with treatment costs exceeding $1B.
- Average patient survival time with existing treatments: 15.6 months
- Rate of tumor recurrence: 97%
- Survival statistic at 5 years after diagnosis: less than 4%